Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab
Published inEuropean journal of nuclear medicine and molecular imaging, vol. 31, no. 4, p. 547-554
Collection
- Open Access - Licence nationale Springer
Publication date2004
Abstract
Keywords
- Alpha Particles/therapeutic use
- Animals
- Antibodies
- Monoclonal/pharmacokinetics/therapeutic use
- Antibodies
- Monoclonal
- Murine-Derived
- Antineoplastic Agents/therapeutic use
- Apoptosis/radiation effects
- Cell Line
- Tumor
- Cell Survival/radiation effects
- Dose-Response Relationship
- Drug
- Drug Delivery Systems/methods
- Evidence-Based Medicine/methods
- Female
- Leukemia/drug therapy/metabolism/radiotherapy
- Mice
- Mice
- SCID
- Organ Specificity
- Radioimmunotherapy/methods
- Radiopharmaceuticals/therapeutic use
- Reproducibility of Results
- Survival
- Tissue Distribution
- Treatment Outcome
Research groups
Citation (ISO format)
BEYER, Gerd-Jurgen et al. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. In: European journal of nuclear medicine and molecular imaging, 2004, vol. 31, n° 4, p. 547–554. doi: 10.1007/s00259-003-1413-9
Main files (1)
Article (Published version)
Identifiers
- PID : unige:26051
- DOI : 10.1007/s00259-003-1413-9
- PMID : 14722680
Journal ISSN1619-7070